Cipla’s UK subsidiary enters into JVA with Cooper Pharma, PHI

10 Feb 2015 Evaluate

Cipla’s - wholly owned subsidiary, Cipla (EU), UK has entered into a joint venture agreement (JVA) with Cipla’s existing business partners in Morocco - Societe Marocaine De Cooperation Pharmaceutique (Cooper Pharma) and The Pharmaceutical Institute (PHI). Cipla has established a strong presence in Morocco for over a decade via its business partners.

This JV will enable Cipla to establish a front-end presence in Morocco’s pharmaceutical market, becoming the launch vehicle for Cipla’s portfolio while leveraging the commercial strengths of partners. The initial focus of the JV shall be respiratory and neurology products and it shall also invest in setting up a manufacturing facility in Morocco.

As per the agreement, Cipla (EU) will hold 60% stake in the JV, while Cooper Pharma and PHI shall together hold 40% stake. Cipla (EU)’s expected investment in cash in the JV is estimated at up to $15 million. The transaction remains subject to conditions precedent and applicable regulatory approvals.

Cipla Share Price

1498.00 6.60 (0.44%)
31-Dec-2025 10:43 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1722.05
Dr. Reddys Lab 1267.50
Cipla 1498.00
Zydus Lifesciences 913.20
Lupin 2086.50
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×